A Phase II Study of CP-751,871 in Patients With Recurrent and/or Metastatic Squamous Head and Neck Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2016
At a glance
- Drugs Figitumumab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 03 Jul 2012 This trial is recruiting in France and has been completed in Belgium.
- 03 Mar 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 28 Oct 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.